Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial.

Peppe J, Porzio A, Davidson DM.

Br J Clin Pharmacol. 2008 Jul;66(1):102-9. doi: 10.1111/j.1365-2125.2008.03151.x. Epub 2008 Mar 13.

2.

Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.

Louie TJ, Peppe J, Watt CK, Johnson D, Mohammed R, Dow G, Weiss K, Simon S, John JF Jr, Garber G, Chasan-Taber S, Davidson DM; Tolevamer Study Investigator Group.

Clin Infect Dis. 2006 Aug 15;43(4):411-20. Epub 2006 Jul 11.

PMID:
16838228
3.

Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.

Scheinfeld N, Biggers K.

Curr Opin Investig Drugs. 2008 Aug;9(8):913-24. Review.

PMID:
18666039
5.

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.

Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S.

JAMA. 2015 May 5;313(17):1719-27. doi: 10.1001/jama.2015.3725.

PMID:
25942722
7.

Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.

Geisser P, Banké-Bochita J.

Arzneimittelforschung. 2010;60(6a):362-72. doi: 10.1055/s-0031-1296301.

PMID:
20648928
8.

Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures.

Fountain NB, Krauss G, Isojarvi J, Dilley D, Doty P, Rudd GD.

Epilepsia. 2013 Jan;54(1):58-65. doi: 10.1111/j.1528-1167.2012.03543.x. Epub 2012 Jun 18.

9.

Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.

Barbhaiya RH, Marathe PH, Greene DS, Mayol RF, Shukla UA, Gammans RR, Pittman KA, Robinson D.

J Clin Pharmacol. 1995 Oct;35(10):974-84.

PMID:
8568015
10.

A Phase 1 dose-ranging study examining the effects of a superabsorbent polymer (CLP) on fluid, sodium and potassium excretion in healthy subjects.

Henderson LW, Dittrich HC, Strickland A, Blok TM, Newman R, Oliphant T, Albrecht D.

BMC Pharmacol Toxicol. 2014 Jan 25;15:2. doi: 10.1186/2050-6511-15-2.

12.

Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.

Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB.

Epilepsy Behav. 2015 Nov;52(Pt A):119-27. doi: 10.1016/j.yebeh.2015.09.006. Epub 2015 Sep 27.

13.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
14.

Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.

Rosenberg G, Angel I, Kozak A.

Br J Clin Pharmacol. 2005 Jul;60(1):7-16.

15.

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.

Clin Ther. 2006 Jan;28(1):55-72.

PMID:
16490580
16.

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.

Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.

Clin Ther. 2010 Jun;32(6):1188-204. doi: 10.1016/j.clinthera.2010.06.004.

PMID:
20637971
17.

Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.

Vaughan D, Speed J, Medve R, Andrews JS.

Clin Ther. 2010 Jan;32(1):146-60. doi: 10.1016/j.clinthera.2010.01.006.

PMID:
20171420
18.

Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.

Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH Jr.

Antimicrob Agents Chemother. 2008 Jun;52(6):2190-5. doi: 10.1128/AAC.00041-08. Epub 2008 Apr 7.

19.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Feagan BG, Macdonald JK.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD000543.

PMID:
23076889
20.

A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.

Sheldon E, Kitchin N, Peng Y, Eiden J, Gruber W, Johnson E, Jansen KU, Pride MW, Pedneault L.

Vaccine. 2016 Apr 19;34(18):2082-91. doi: 10.1016/j.vaccine.2016.03.010. Epub 2016 Mar 15.

PMID:
26993331

Supplemental Content

Support Center